These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37516904)

  • 21. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case analysis of long-term negative psychological responses to psychedelics.
    Bremler R; Katati N; Shergill P; Erritzoe D; Carhart-Harris RL
    Sci Rep; 2023 Sep; 13(1):15998. PubMed ID: 37749109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. UK medical students' self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study.
    Song-Smith C; Jacobs E; Rucker J; Saint M; Cooke J; Schlosser M
    BMJ Open; 2024 Mar; 14(3):e083595. PubMed ID: 38485474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
    Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms.
    Morgan CJA
    Addiction; 2023 Dec; 118(12):2455-2456. PubMed ID: 37919093
    [No Abstract]   [Full Text] [Related]  

  • 26. Factors associated with the use of psychedelics, ketamine and MDMA among sexual and gender minority youths in Canada: a machine learning analysis.
    Dharma C; Liu E; Grace D; Logie C; Abramovich A; Mitsakakis N; Baskerville B; Chaiton M
    J Epidemiol Community Health; 2024 Mar; 78(4):248-254. PubMed ID: 38262735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
    Nygart VA; Pommerencke LM; Haijen E; Kettner H; Kaelen M; Mortensen EL; Nutt DJ; Carhart-Harris RL; Erritzoe D
    J Psychopharmacol; 2022 Aug; 36(8):932-942. PubMed ID: 35924888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting.
    Argento E; Strathdee SA; Tupper K; Braschel M; Wood E; Shannon K
    BMJ Open; 2017 Sep; 7(9):e016025. PubMed ID: 28939573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Belief changes associated with psychedelic use.
    Nayak SM; Singh M; Yaden DB; Griffiths RR
    J Psychopharmacol; 2023 Jan; 37(1):80-92. PubMed ID: 36317643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey.
    Barnett BS; Beaussant Y; King F; Doblin R
    J Psychoactive Drugs; 2022; 54(3):269-277. PubMed ID: 34409921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics.
    Kruger DJ; Barron J; Herberholz M; Boehnke KF
    J Psychoactive Drugs; 2023; 55(5):650-659. PubMed ID: 37353935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists.
    Berger JJ; Fitzgerald PB
    Australas Psychiatry; 2023 Apr; 31(2):190-194. PubMed ID: 36779819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. With great power comes great vulnerability: an ethical analysis of psychedelics' therapeutic mechanisms proposed by the REBUS hypothesis.
    Villiger D; Trachsel M
    J Med Ethics; 2023 Nov; 49(12):826-832. PubMed ID: 37045591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychedelic drug use and schizotypy in young adults.
    Lebedev AV; Acar K; Garzón B; Almeida R; Råback J; Åberg A; Martinsson S; Olsson A; Louzolo A; Pärnamets P; Lövden M; Atlas L; Ingvar M; Petrovic P
    Sci Rep; 2021 Jul; 11(1):15058. PubMed ID: 34301969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.
    Davis AK; Agin-Liebes G; España M; Pilecki B; Luoma J
    J Psychoactive Drugs; 2022; 54(4):309-318. PubMed ID: 34468293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
    Sweat NW; Bates LW; Hendricks PS
    J Psychoactive Drugs; 2016; 48(5):344-350. PubMed ID: 27719438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Epidemiology of hallucinogenic drug use in the Netherlands].
    van Laar MW; van Miltenburg CJA
    Tijdschr Psychiatr; 2020; 62(8):684-692. PubMed ID: 32816297
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.